Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of GB 08 for Somatotropin deficiency

Trial Profile

A clinical trial of GB 08 for Somatotropin deficiency

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 08 (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions

Most Recent Events

  • 06 Jun 2024 New trial record
  • 30 May 2024 According to a Kexing Biopharm media release, company recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, approving its clinical trial application for GB08 injection solution developed independently by the company. NMPA approves clinical trial application for GB 08 in Somatotropin deficiency.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top